A San Diego-based developer of targeted cancer drugs is hoping its medicine can shrink tumors in non-small cell lung cancer caused by specific genetic alterations.
STAT Plus: Watch this company: Turning Point Therapeutics shares pop 57% after IPO
News
STAT Plus: Halozyme?s lead drug fails; company will cut 55% of workforce in bid for profitability
Halozyme, a San Diego-based biotech, said that its lead drug, for pancreatic cancer, had failed to extend the lives of patients in a clinical trial. […]